癌症疼痛市场规模、份额和增长分析（按药物类别、适应症、分销渠道、给药途径、最终用户和地区）- 2025-2032 年行业预测

2023 年全球癌症疼痛市场规模价值 75 亿美元，预计将从 2024 年的 79.2 亿美元增长到 2032 年的 122.5 亿美元，预测期内（2025-2032 年）的复合年增长率为 5.6%。

全球癌症疼痛市场正在经历显着增长，这归因于癌症发病率增加、人口老化、医疗支出增加以及医疗保健公司研发倡议加大等几个关键因素。根据国际癌症研究机构的数据，2020 年美国诊断出的新癌症病例约 180 万例，癌症相关死亡病例约 606,520 例。老化社会特别容易受到各种癌症的侵害，据报道，乳癌的诊断平均年龄为 61 岁，结直肠癌的诊断平均年龄为 68 岁，肺癌的诊断平均年龄为 70 岁，前列腺癌的诊断平均年龄为 66 岁。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 监管分析
• 技术分析

癌症疼痛市场规模（按药物类别和复合年增长率） (2025-2032)

• 市场概况
• 阿片类药物
• 羟可酮
• 氢可酮
• NSAIDs
• Ibuprofen
• 萘普生
• 其他的

癌症疼痛市场规模（按适应症和复合年增长率） (2025-2032)

• 市场概况
• 肺癌
• 大肠直肠癌
• 乳癌
• 摄护腺癌
• 血癌
• 其他的

癌症疼痛市场规模（按分销管道和复合年增长率） (2025-2032)

• 市场概况
• 医院药房
• 网路药局
• 零售药局

癌症疼痛市场规模（按给药途径和复合年增长率） (2025-2032)

• 市场概况
• 口服
• 肠外
• 其他的

癌症疼痛市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概况
• 医院
• 居家照护
• 专科门诊
• 其他的

癌症疼痛市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Pfizer（USA）
• Johnson & Johnson（USA）
• Purdue Pharma（USA）
• Novartis（Switzerland）
• Heron Therapeutics（USA）
• Teva Pharmaceutical Industries（Israel）
• Eli Lilly and Company（USA）
• AstraZeneca（UK）
• GlaxoSmithKline（UK）
• Merck & Co., Inc.（USA）

结论和建议

Global Cancer Pain Market size was valued at USD 7.5 billion in 2023 and is poised to grow from USD 7.92 billion in 2024 to USD 12.25 billion by 2032, growing at a CAGR of 5.6% during the forecast period (2025-2032).

The global cancer pain market is experiencing significant growth, driven by several key factors: the increasing prevalence of cancer, an aging demographic, rising healthcare expenditures, and heightened research and development initiatives by healthcare companies. In 2020, the American Cancer Society noted approximately 1.8 million new cancer diagnoses and about 606,520 cancer-related fatalities in the U.S. Moreover, colorectal cancer was responsible for around 1,065,960 new cases globally, according to the International Agency for Research on Cancer. The aging population is particularly vulnerable to various cancers, with median diagnosis ages reported as 61 for breast cancer, 68 for colorectal cancer, 70 for lung cancer, and 66 for prostate cancer, as highlighted by the National Cancer Institute.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Pain market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Pain Market Segments Analysis

Global Cancer Pain Market is segmented by Drug Class, Indication, Distribution Channel, Route of Administration, End User and region. Based on Drug Class, the market is segmented into Opioids, Oxycodone, Hydrocodone, NSAIDs, Ibuprofen, Naproxen and Others. Based on Indication, the market is segmented into Lung cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Blood Cancer and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy and Retail Pharmacy. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on End User, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Pain Market

The Global Cancer Pain market is significantly driven by technological advancements in pain management strategies, innovative drug delivery systems, and the development of personalized treatment options. These innovations not only improve the effectiveness of pain relief methods but also make them more accessible to patients suffering from cancer-related pain. As research and development continue to evolve, the emergence of new technologies is expected to optimize patient outcomes, streamline treatment protocols, and ensure that individuals have better access to the most suitable pain management solutions for their unique needs. This dynamic landscape continues to shape the market and enhance the quality of life for those affected.

Restraints in the Global Cancer Pain Market

The growth of the global cancer pain market may be hampered by the risks of drug tolerance and dependence that can arise from the use of pain medications, along with the possibility of experiencing a range of side effects. These factors contribute to concerns among healthcare providers and patients alike, potentially influencing their willingness to utilize certain pharmacological interventions. Additionally, the fear of adverse reactions may prompt individuals to seek alternative pain management strategies, further restricting the market's expansion. Consequently, addressing these challenges is essential for promoting a more favorable environment for growth within this crucial sector.

Market Trends of the Global Cancer Pain Market

The Global Cancer Pain market is witnessing a significant trend towards personalized pain management, driven by an increasing emphasis on individualized treatment strategies that leverage genetic and molecular profiling. This shift reflects a broader movement in healthcare to tailor therapies to the unique characteristics of patients, enhancing the efficacy and outcome of pain management in cancer care. By integrating advanced diagnostics and biomarker analysis, stakeholders in the market are innovating targeted pain relief solutions designed to optimize patient comfort and overall quality of life. This trend is expected to accelerate growth in the market, fostering advancements in treatment protocols and patient adherence.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Analysis
• Technology Analysis

Global Cancer Pain Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Opioids
• Oxycodone
• Hydrocodone
• NSAIDs
• Ibuprofen
• Naproxen
• Others

Global Cancer Pain Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Lung cancer
• Colorectal Cancer
• Breast Cancer
• Prostate Cancer
• Blood Cancer
• Others

Global Cancer Pain Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Cancer Pain Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral
• Others

Global Cancer Pain Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Cancer Pain Market Size & CAGR (2025-2032)

• North America (Drug Class, Indication, Distribution Channel, Route of Administration, End User)
  • US
  • Canada
• Europe (Drug Class, Indication, Distribution Channel, Route of Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Indication, Distribution Channel, Route of Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Indication, Distribution Channel, Route of Administration, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Indication, Distribution Channel, Route of Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Purdue Pharma (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Heron Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations